Bionano Genomics, Inc. (NASDAQ:BNGO) Q4 2025 Earnings Call Transcript March 23, 2026 Bionano Genomics, Inc. reports earnings ...
The market misinterprets past COVID-era revenue growth for 10x Genomics and fails to integrate current sector growth. Read ...
A free open-access webinar will introduce the Cancer Genome Interpreter (CGI), an advanced bioinformatics tool to interpret mutations in cancer genomes developed by IRB Barcelona and co-created with ...
Te Whatu Ora starts genomics testing pilot. Te Whatu Ora Health New Zealand has launched a two-year pilot to deliver local ...
Good day, and welcome to the Bionano Fourth Quarter and Full Year 2025 Earnings Conference Call. Today's conference is being recorded. At this time, I would like to turn the conference over to Webb ...
Bionano Genomics BNGO just pulled back the curtain on its fourth-quarter results, and the message is clear: the company is ...
Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the fourth quarter and full year ended December 31, 2025. "2025 demonstrated the momentum we built as a business,” commented ...
Bionano Genomics (NASDAQ: BNGO) participated in the 2026 American College of Medical Genetics and Genomics Annual Meeting (ACMG), held March 14–18 in Baltimore, Maryland. Twelve studies, representing ...
Learn more about whether Revvity, Inc. or 10x Genomics, Inc. is a better investment based on AAII's A+ Investor grades, which ...
Independent clinical validation strengthens ABL’s leadership in the fast‑growing HIV drug‑resistance testing market ABL ...
Researchers at Memorial Sloan Kettering Cancer Center (MSK) have made an important discovery about how genetic mutations in breast cancer patients can interact and drive resistance to certain drugs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results